
Grail secures FDA approval for a study on the Galleri multicancer early detection test in Medicare beneficiaries to assess its effectiveness in reducing late-stage cancer diagnoses.


coremsg

Grail announced a step that may help move the company closer to securing Medicare reimbursement for its Galleri multicancer blood test, sold in the US since 2021.

Grail Gets FDA OK for Study of Cancer Blood Test

grail-receives-fda-approval-for-cancer-blood-test-study


Grail Receives FDA Approval for Cancer Blood Test Study
